Response to: “Special editorial: When prescribing Janus kinase inhibitors for dermatologic conditions, be mindful of the Food and Drug Administration's September 1, 2021, data safety communication”

TY - JOUR

T1 - Response to

T2 - “Special editorial: When prescribing Janus kinase inhibitors for dermatologic conditions, be mindful of the Food and Drug Administration's September 1, 2021, data safety communication”

AU - Rick, Jonathan W.

AU - Lio, Peter

AU - Hsiao, Jennifer L.

AU - Shi, Vivian Y.

N1 - Funding Information: Dr Shi is on the board of directors for the Hidradenitis Suppurativa Foundation, is a stock shareholder of Learn Health, and has served as an advisory board member, investigator, speaker, and/or received research funding from Sanofi Genzyme, Regeneron, AbbVie, Eli Lilly, Novartis, Sun Pharma, LEO Pharma, Pfizer, Incyte, Boehringer Ingelheim, Aristea Therapeutics, Menlo Therapeutics, Dermira, Burt’s Bees, Galderma, Kiniksa, UCB, TARGET PharmaSolutions, Altus Lab/CQuell, MYOR, Polyfins Technology, GpSkin, Skin Actives Scientific and the National Eczema Association. Dr Hsiao is on the board of directors for the Hidradenitis Suppurativa Foundation and is a consultant for Novartis and speaker for AbbVie. Dr Lio reports research grants/funding from the National Eczema Association, Regeneron/Sanofi Genzyme, and AbbVie; is on the speaker’s bureau for Regeneron/Sanofi Genzyme, Pfizer, and L’Oreal; and reports consulting/advisory board work for UCB, Dermavant, Regeneron/Sanofi Genzyme, Dermira, Pfizer, LEO Pharmaceuticals, AbbVie, Kiniksa, Eli Lilly, Micreos (stock options), La Roche Posay/L’Oreal, Pierre Fabre, Johnson & Johnson, Unilever, Menlo Therapeutics, Theraplex, IntraDerm, Exeltis, AOBiome, Realm Therapeutics, Franklin Bioscience/Altus Labs (stock options), Verrica, TopMD, Arbonne, Amyris, Bodewell, and Burt’s Bees. In addition, Dr Lio has a patent pending for a Theraplex product, with royalties paid, and is a board member and Scientific Advisory Committee member of the National Eczema Association. Dr Rick has no conflicts of interest to declare.

PY - 2022/7

Y1 - 2022/7

UR - http://www.scopus.com/inward/record.url?scp=85131956958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85131956958&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2022.03.019

DO - 10.1016/j.jaad.2022.03.019

M3 - Letter

C2 - 35307489

AN - SCOPUS:85131956958

SN - 0190-9622

VL - 87

SP - e33-e34

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

IS - 1

ER -